Skip to content

Efficacy of Abhrakadi Yog and Nisha-Amalaki Yog in Prediabetes- A comparative study

Comparative Study of Abhrakadi Yog and Nisha-Amalaki Yog with Lifestyle Management in Prediabetes: A Two-arm Open-labelled Randomised Clinical Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/100718
Enrollment
120
Registered
2026-01-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases

Interventions

None listed

Sponsors

Department of Kayachikitsa, College of Ayurved, Bharati Vidyapeeth, deemed to be University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Individuals presenting to Kayachikitsa OPD IPD, Bharati Ayurved Hospital, having classical symptoms of Prameha poorvaroopa and/or polyuria, polydipsia, polyphagia, nocturia, and/ or fulfilling the WHO criteria as stated in the ICMR guidelines for prediabetes, i.e. fasting blood glucose between 110-124mg/dl and HbA1c level between 5.7-6.4%, Patients with history of diabetes mellitus in parents or siblings, Women with polycystic ovarian syndrome or history of gestational diabetes mellitus.

Exclusion criteria

Exclusion criteria: Patients diagnosed with any type of diabetes (Fasting glucose 120mg/dl or HbA1c=6.5%), Patients with comorbid conditions- any malignancy, Chronic renal failure, Hypertension, Ischemic heart disease, Cerebro-vascular accident, Liver cirrhosis or Chronic liver disease, etc., Individuals on systemic steroids or any immunosuppressant drugs or any drugs that induce diabetes like glucocorticoids and androgen blockers cardiovascular drugs, especially antiplatelets, anticoagulants, statins, beta-blockers and diuretics, antipsychotics, especially clozapine, olanzapine and quetiapine, antiretrovirals (protease inhibitors and non-reverse transcriptase inhibitors - NRTIs),Subjects taking anti-obesity medication, pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
1. Improvement in Prameha Purvarupa Risk Score 2. Improvement in Fasting blood glucose levels 3. Improvement in HbA1cTimepoint: 1. 8 weeks 2. 8 weeks 3. 12 weeks

Secondary

MeasureTime frame
1. Improvement in Indian Diabetes Risk Score 2. Improvement in BMITimepoint: 3 months

Countries

India

Contacts

Public ContactDr D L Shinde

Bharati Vidyapeeth (deemed to be University)

dshinde249@gmail.com9890111954

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026